The Federal Trade Commission in September filed an administrative complaint against the three largest pharmacy benefit managers (PBMs) in the US. The FTC alleged that Caremark Rx, Express Scripts, and Zinc Health Services employ anticompetitive rebating practices that have hiked the price of insulin for consumers.
Developments in this suit and a possible resolution in the coming year could be a big step forward to breaking down PBM domination over prescription drug pricing and bringing back business to smaller pharmacies. It’s also safe to assume that the FTC will take additional action against entities involved in drug pricing in 2025. ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.